Skip to main content
OpenTrials
Completed

NCT Number: NCT03037411

A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries

The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medizinische Universität Graz, Graz, Austria

Loading trial locations.

About this study

A European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.

The objective of the study is to collect additional data including health economics data to support the use of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects age 18 and older
  • Subject is willing and able to provide written consent before any study-specific test or procedure is performed and agrees to attend all follow-up visits
  • De novo, restenotic or (re)occluded lesions in the native femoro-popliteal arteries, with reference vessel diameter (RVD) ranging from 4.0-6.0 mm, suitable for endovascular treatment

Exclusion criteria

  • Subject is pregnant or planning to become pregnant during the course of the study
  • Life expectancy of less than 1 year (which is defined as documented life expectancy less than 12 months due to other medical co-morbid condition(s) that could limit the subject's ability to participate in the clinical follow-up, limit the subject's compliance with the standard of care follow-up, or impact the scientific integrity of the trial)
  • Known allergy to the ELUVIA stent system or any of its components, concomitant medication, contrast agents (that cannot be medically managed)
  • Subject enrolled in an investigational study that has not reached primary endpoint at the time of enrollment or that clinically interferes with the current study assessments (Note: studies requiring extended follow-up for products that were investigational, but have become commercially available since then are not considered investigational studies)

Treatment and study plan

Peripheral stenting

Device

stent implantation during the index procedure

Primary outcomes

  1. Participant Quality-of-Life Changes Via EuroQol 5 Dimension (EQ-5D) Questionnaire.

    Time frame: Baseline,12 and 24 months

    The EQ-5D assesses five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) of health-related quality of life responses assigned by the participants. The values are anchored at 1 (best) to 0 (worst). The vales for the visual analog score takes values from 100 (best) to 0 (worst). The index value is comparable across the baseline, 12- and 24-Months timepoints.

Secondary outcomes

  1. Number of Participants With Improvement on the Walking Impairment Questionnaire

    Time frame: 12 and 24 months

    Improvement was calculated by comparing the scores from 12- and 24-Months to the baseline scores and presenting the number of participants that showed improvement at 12- and 24-Months. The WIQ measures the improvement as reported by participants in their walking distance, walking speed, stair-climbing ability and improvement in their PAD symptoms pre-procedure (baseline) compared to 12 months and compared to 24 months. The improvement at those time points is measured as percent improvement.

  2. Number of Participants With Improved Rutherford Classification Indicating Rate of Primary and Secondary Sustained Clinical Improvement

    Time frame: 12 and 24 months

    The Rutherford Classification describes the different stages of peripheral artery disease (PAD) from a score of 0 (no PAD) to 6 (critical limb ischemia with major tissue loss). The percentages represent the percent of participants that had sustained clinical improvement from baseline to 12 months and baseline to 24 months. Sustained clinical improvement means their Rutherford Class improved by one or more categories compared with baseline.

    Number of participants with improved Rutherford Classification at 12- and 24-Months when compared to baseline.

    Primary Sustained Clinical Improvement is improvement in Rutherford Classification of one or more categories as compared to baseline without the need for repeat target lesion revascularization (TLR).

    Secondary Sustained Clinical Improvement is improvement in Rutherford classification of one or more categories as compared to baseline including those participants with repeat TLR.

  3. Number of Participants With Hemodynamic Improvement

    Time frame: 12 and 24 months

    Number of participants with improvement in Ankle-Brachial Index (ABI) at 12- and 24-Months compared to baseline.

    Hemodynamic Improvement is defined as an increase in ABI of >= 0.10 or to an ABI >= 0.90 as compared to baseline without the need for repeat TLR. The ABI measures the arterial pressure in the leg compared to the arterial pressure in the arm. The higher the value, the better the blood flow. Improvement is defined as an increase in the ABI by greater than or equal to 0.10 compared with baseline or to an ABI greater than or equal to 0.90. The percentages in the table represent the patients that demonstrated an improvement in their ABI from baseline to 12 months and baseline to 24-months.

  4. Health Care Utilization

    Time frame: 1, 6, 12 and 24 months

    Changes in healthcare utilization over time

Other outcomes

  1. Number of Participants With Technical Success of the Stenting Procedure

    Time frame: During stenting procedure

    Number of participants that successfully received Eluvia stent. Technical success defined as implanted and achieving residual angiographic stenosis no greater than 30% assessed visually.

  2. Number of Participants With Procedural Success of the Stenting Procedure

    Time frame: within 24 hours of stenting procedure

    Number of participants with successful procedures. Procedural success defined as technical success with no major adverse events (MAEs) noted within 24 hours of the stenting procedure.

  3. Number of Participants With a Major Adverse Event (MAE)

    Time frame: 12 and 24 months

    Number of participants with Clinical Events Committee (CEC) adjudicated MAEs at 12- and 24-Months cumulatively. The MAEs are defined as all causes of death, target limb major amputation and/or Target Lesion Revascularization rate. A participant can be present in more than one sub-category.

  4. Percentage of Participants With Primary Patency at 12- and 24-Months Post Procedure

    Time frame: 12 and 24 months

    The numbers represent the percentage of patients that were event free at 12 and 24 months (i.e. didn't have a TLR).

  5. Number of Participants With a Clinically-driven Target Lesion Revascularization (TLR)

    Time frame: 12 and 24 months

    The cumulative number of participants that received a clinically-driven target lesion revascularization after the stenting procedure.

  6. Number of Participants With a Clinically-driven Target Vessel Revascularization (TVR)

    Time frame: 12 and 24 months

    The cumulative number of participants that received a clinically-driven target vessel revascularization after the stenting procedure.

  7. Participant Distribution on the Rutherford Classification at Baseline, 12-, and 24- Month

    Time frame: Baseline, 12 and 24 months

    Rutherford Classification:

    • Asymptomatic - Normal Treadmill /stress test
    • Mild claudication - Completes treadmill exercise; ankle pressure (AP) after exercise <50mm Hg, but >25 mm Hg less than blood pressure (BP)
    • Moderate claudication - Between categories 1 and 3
    • Severe claudication - Cannot complete treadmill exercise and AP after exercise <50 mm Hg
    • Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); toe pressure (TP) <30 mm Hg
    • Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal edema - Resting AP <60 mm Hg, ankle or metatarsal (MT) PVR flat or barely pulsatile; TP <40 mm Hg
    • Major tissue loss-extending above MT level - Same as Category 5

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease

Acronym: REGAL

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Jan 31, 2017
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.